UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000014477 |
|---|---|
| Receipt number | R000016841 |
| Scientific Title | Feasibility study of pemetrexed / bevacizumab / erlotinib in chemotherapy naïve patients with non- small cell lung cancer harboring EGFR mutation |
| Date of disclosure of the study information | 2014/07/04 |
| Last modified on | 2017/07/06 15:05:10 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Feasibility study of pemetrexed / bevacizumab / erlotinib in chemotherapy naïve patients with non- small cell lung cancer harboring EGFR mutation
Acronym
Feasibility Study of pemetrexed / bevacizumab / erlotinib
Scientific Title
Feasibility study of pemetrexed / bevacizumab / erlotinib in chemotherapy naïve patients with non- small cell lung cancer harboring EGFR mutation
Scientific Title:Acronym
Feasibility Study of pemetrexed / bevacizumab / erlotinib
Region
| Japan |
Condition
Condition
Non-Small Cell Lung Cancer,
Non-Squamous cell lung cancer
Classification by specialty
| Pneumology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To determine recommended dose of Pemetrexed/Bevacizumab/Erlotinib in chemotherapy naïve patients with non- small cell lung cancer harboring EGFR mutation
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Phase I
Assessment
Primary outcomes
Feasibility of Pemetrexed/Bevacizumab/Erlotinib
Key secondary outcomes
Anti-tumor efficacy
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
If four or more of the 6-12 patients who had been originally allocated to the level 0 experienced DLT, additional 6-12 patients were enrolled to the level -1. If four or more patients experienced DLT at this level, we conclude there was no feasibility of this combination.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1)Histology/cytology-proven non-squamous non-small cell lung cancer
2)Stage IIIB, IV and unsuitable for radiotherapy and postoperative recurrence
3)EGFR mutant patients(exclude T790M mutation)
4)With one or more measurable disease based on RECIST
5)Performance status(ECOG): 0-1
6)Age 20<80
7)Adequate organ function
8)Written informed consent
Key exclusion criteria
1) Interstitial pneumonia/lung fibrosis on chest X-ray
2) History of chest radiation therapy
3) History or complication of hemoptysis with 2.5ml per time or more and Continuous bloody phlegm more than 1 week or complication of bloody phlegm treated with continuous oral hemostatic agent. History or complication of bloody phlegm treated with infusional hemostatic agent.
4) Evidence of tumor invading a perihilar blood vessel, heart and major blood vessel on imaging
5) Evidence of tumor invading segmental bronchus
6) Symptomatic brain metastasis
7) Active hepatic disease
8) Having serious complications
9) Uncontrolled ascites, pleural effusion or cardiac effusion
10) History of multiple malignancies within 3 years
11) Planning of surgery during the trial
12) A pregnant woman, a nursing girl and woman with the possibility (intention) of the pregnancy, and
13) Having serious mental disorder
14) Previous drug allergy
15) Those judged to be not suitable by the attending physician
Target sample size
12
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Masao Ichiki |
Organization
National Hospital Organization Kyushu Medical Center
Division name
Department of Respiratory Medicine
Zip code
Address
1-8-1 Jigyohama Chuo-ku, Fukuoka 810-8563, Japan
TEL
092-852-0700
ichiki@kyumed.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Masao Ichiki |
Organization
National Hospital Organization Kyushu Medical Center
Division name
Department of Respiratory Medicine
Zip code
Address
1-8-1 Jigyohama Chuo-ku, Fukuoka 810-8563, Japan
TEL
092-852-0700
Homepage URL
ichiki@kyumed.jp
Sponsor or person
Institute
National Hospital Organization Kyushu Medical Center,Department of Respiratory Medicine
Institute
Department
Personal name
Funding Source
Organization
National Hospital Organization Kyushu Medical Center
Department of Respiratory Medicine
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
国立病院機構 九州医療センター呼吸器内科（福岡県）
Other administrative information
Date of disclosure of the study information
| 2014 | Year | 07 | Month | 04 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2014 | Year | 04 | Month | 24 | Day |
Date of IRB
Anticipated trial start date
| 2014 | Year | 07 | Month | 03 | Day |
Last follow-up date
| 2018 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
| 2018 | Year | 12 | Month | 31 | Day |
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2014 | Year | 07 | Month | 04 | Day |
Last modified on
| 2017 | Year | 07 | Month | 06 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016841
